A treatment option for adults with relapsed or refractory multiple myeloma who have received at least four treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multilple myeloma, and their cancer has come back or did not respond to prior treatment. TECVAYLITM is approved based on patient response. Data are not yet available to show if TECVAYLITM improves survival or symptoms.
It is not known if TECVAYLITM is safe and effective in children.
Sign up now to stay informed about the latest updates on TECVAYLI™. Ask your doctor if TECVAYLI™ may be right for you.
Download this brochure to review the Medication Guide and additional information about getting started with TECVAYLI™.Get the Guide
There are support and resource options for TECVAYLI™ .Explore Now
Sign up for the latest information about TECVAYLI™